Prince Charles Hospital

Running trials

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Source

• Recruiting

  A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  NCT07567001· Phase 3· Source

• Recruiting

  Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

  NCT07318597· Phase 2· Source

• Not yet recruiting

  Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform

  NCT07421115· Source

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Active, not recruiting

  A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

  NCT07036523· Phase 2· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

  NCT07190248· Phase 3· Source

• Recruiting

  AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions

  NCT06959524· Source

• Recruiting

  EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  NCT07064473· Phase 3· Source

• Recruiting

  ELEVATE-HFpEF Clinical Study

  NCT06678841· Source

• Recruiting

  A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy

  NCT06979375· Phase 2· Source

• Recruiting

  PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

  NCT06855329· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Source

• Active, not recruiting

  ASCEND CSP IDE Study

  NCT06830746· Source

• Active, not recruiting

  A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

  NCT06588686· Phase 2· Source

• Recruiting

  A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  NCT06561386· Phase 3· Source

• Active, not recruiting

  A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

  NCT06238622· Phase 3· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

  NCT06312137· Phase 3· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Source

• Recruiting

  Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  NCT05943535· Phase 3· Source

• Active, not recruiting

  Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

  NCT06008756· Phase 3· Source

• Active, not recruiting

  A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)

  NCT06081894· Phase 3· Source

• Active, not recruiting

  Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)

  NCT07579390· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Active, not recruiting

  Real World Data Collection in Subjects Treated With the FARAPULSE Pulsed Field Ablation System

  NCT05501873· Source

• Recruiting

  Study to Assess Amphotericin B Cystetic for Inhalation (ABCI) Doses in Healthy Volunteers & People with Cystic Fibrosis

  NCT05802264· Phase 1· Source

• Active, not recruiting

  Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD

  NCT05612035· Phase 2· Source

• Active, not recruiting

  Advanced NanoTherapies Dual-API DCB to Treat De-Novo Lesions in Patients With Symptomatic Coronary Artery Disease

  NCT05521542· Source

• Active, not recruiting

  RESPONDER-HF Trial

  NCT05425459· Source

• Active, not recruiting

  A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

  NCT05444257· Phase 3· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

  NCT05508789· Phase 3· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· Source

• Recruiting

  Polysomnographic Titration of Non-invasive Ventilation in Motor Neurone Disease

  NCT05136222· Source

• Active, not recruiting

  Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

  NCT05059522· Phase 3· Source

• Enrolling by invitation

  Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

  NCT04848506· Phase 2/3· Source

• Active, not recruiting

  Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia

  NCT05524077· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Source

• Recruiting

  The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study

  NCT04204915· Source

• Enrolling by invitation

  A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

  NCT03683186· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

  NCT04083339· Phase 3· Source

• Active, not recruiting

  A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

  NCT03887455· Phase 3· Source

• Recruiting

  The EXCEL Registry of Patients Requiring ECMO

  NCT03793257· Source

• Active, not recruiting

  Reducing Lung CongestIon Symptoms in Advanced Heart Failure

  NCT03499236· Source

• Active, not recruiting

  PARTNER 3 Trial - Mitral Valve in Valve

  NCT03193801· Source

• Active, not recruiting

  Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients

  NCT02922036· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03178552· Phase 2/3· Source

• Active, not recruiting

  Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC

  NCT03057106· Phase 2· Source

Showing 50 of 51.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Heart failure6 recruiting
• Idiopathic pulmonary fibrosis5 recruiting
• High blood pressure3 recruiting
• Lung cancer3 recruiting
• Coronary artery disease2 recruiting
• Obesity2 recruiting
• Pulmonary arterial hypertension2 recruiting
• ALS (motor neurone disease)1 recruiting
• Asthma1 recruiting
• Cystic fibrosis1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Metastatic breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Source

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· Source

• Completed

  A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

  NCT05076149· Phase 3· Source

• Completed

  A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

  NCT05033080· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  An Implementation Trial to Improve Access to Pulmonary Rehabilitation in People With COPD

  NCT04217330· Source

• Completed

  DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

  NCT04334759· Phase 3· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Source

• Completed

  Preventing Adverse Cardiac Events in COPD

  NCT03917914· Phase 3· Source

• Completed

  Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

  NCT04236609· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Source

• Completed

  Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

  NCT03829319· Phase 3· Source

• Completed

  Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

  NCT03829332· Phase 3· Source

• Completed

  A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

  NCT03626688· Phase 3· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· Source

• Recruiting

  A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

  NCT03394365· Phase 3· Source

• Completed

  CardioMEMS HF System OUS Post Market Study

  NCT02954341· Source

• Completed

  Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

  NCT02539966· Source

• Completed

  Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

  NCT02273375· Phase 3· Source

Trial sites

• Prince Charles Hospital5 trials
• The Prince Charles Hospital12 trials
• The Prince Charles Hospital (Site 0700)1 trial
• The Prince Charles Hospital (Site 0904)1 trial
• The Prince Charles Hospital (Site 2810)1 trial
• The Prince Charles Hospital (Site 2903)1 trial
• 0360062 - The Prince Charles Hospital1 trial
• Prince Charles Hospital8 trials
• The Prince Charles Hospital38 trials
• The Prince Charles Hospital (Adults only)1 trial
• The Prince Charles Hospital - Cardiology Clinical Research Centre3 trials
• The Prince Charles Hospital (Site 0010)1 trial
• The Prince Charles Hospital (Site 0011)1 trial
• The Prince Charles Hospital (TPCH)1 trial
• The Prince Charles Hospital/Internal Medicine & Dementia Research Unit1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Cystic fibrosis22 works · 5 trials